Valuation Charles River Laboratories International, Inc.

Stocks

Market Closed - NYSE 04:00:02 10/10/2026 HKT			5-day change	1st Jan Change
301.79 ^USD	+1.27%		+4.00%	+51.29%

10-06	Charles River Laboratories International, Inc. and Autolomous Launch Apollo Orchestrate Within Charles River's Apollo Platform	CI
09-30	UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	18,941	11,138	12,252	9,520	10,023	14,407	-	-
Change	-	-41.2%	10%	-22.3%	5.29%	43.74%	-	-
Enterprise Value (EV) ¹	21,366	13,616	14,622	11,565	11,946	16,501	16,111	15,729
Change	-	-36.28%	7.39%	-20.91%	3.29%	38.13%	-2.36%	-2.37%
P/E	49.4x	23.1x	25.9x	931x	-70x	73.1x	31.9x	28.2x
PBR	7.45x	3.75x	3.41x	2.75x	3.17x	4.68x	4.12x	3.66x
PEG	-	0.9x	-9.44x	-9.5x	0x	-0x	0x	2.1x
Capitalization / Revenue	5.35x	2.8x	2.97x	2.35x	2.5x	3.68x	3.59x	3.39x
EV / Revenue	6.04x	3.42x	3.54x	2.86x	2.98x	4.21x	4.01x	3.7x
EV / EBITDA	24.3x	13.7x	14.4x	11.6x	12.3x	16.2x	14.5x	13.2x
EV / EBIT	28.8x	16.3x	17.4x	14.3x	15x	20.1x	17.4x	15.2x
EV / FCF	40.2x	46.2x	40x	23.1x	23x	54.9x	31.4x	31.2x
FCF Yield	2.49%	2.17%	2.5%	4.34%	4.34%	1.82%	3.19%	3.21%
Dividend per Share ²	-	-	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-	-	-
EPS ²	7.6	9.48	9.22	0.2	-2.91	4.127	9.456	10.7
Distribution rate	-	-	-	-	-	-	-	-
Net sales ¹	3,540	3,976	4,129	4,050	4,015	3,918	4,015	4,252
EBITDA ¹	879.5	990.9	1,013	996.1	971.5	1,020	1,111	1,193
EBIT ¹	742.1	834	838.8	805.9	793.9	821.8	924.8	1,034
Net income ¹	391	486.2	474.6	10.3	-144.3	190.3	436.9	488
Net Debt ¹	2,425	2,477	2,370	2,046	1,923	2,094	1,704	1,322
Reference price ²	375.34	218.92	238.84	186.16	203.66	301.79	301.79	301.79
Nbr of stocks (in thousands)	50,464	50,879	51,297	51,136	49,215	47,739	-	-
Announcement Date	16/2/22	22/2/23	14/2/24	19/2/25	18/2/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	73.13x	4.21x	16.18x	-.--%	14.41B
WUXI APPTEC CO., LTD.	20.5x	7.3x	14.66x	1.45%	70.61B
ARGENX SE	27.46x	7.51x	23.56x	0.05%	51.01B
LONZA GROUP AG	33.37x	6x	17.96x	0.97%	48.1B
IQVIA HOLDINGS INC.	33.47x	3.25x	14.03x	-.--%	42.78B
REVOLUTION MEDICINES, INC.	-19.64x	203.45x	-20.92x	-.--%	40.67B
BEONE MEDICINES AG	46.95x	5.34x	29.33x	-.--%	40.3B
CELLTRION, INC.	27.18x	7.73x	20.09x	0.42%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	32.53x	6.94x	18.03x	-.--%	28.16B
BIONTECH SE	-14.69x	5.97x	-7.21x	-.--%	24.36B
Average	26.03x	25.77x	12.57x	0.29%	39.1B
Weighted average by Cap.	24.10x	26.74x	13.33x	0.42%